278 related articles for article (PubMed ID: 14518305)
1. [Clinical significance of p53 tumor suppressor gene mutations in adenocarcinoma in Barrett esophagus].
Schneider PM; Hölscher AH; Wegerer S; König U; Becker K; Siewert JR
Langenbecks Arch Chir Suppl Kongressbd; 1998; 115(Suppl I):495-9. PubMed ID: 14518305
[TBL] [Abstract][Full Text] [Related]
2. P53 mutational status improves estimation of prognosis in patients with curatively resected adenocarcinoma in Barrett's esophagus.
Schneider PM; Stoeltzing O; Roth JA; Hoelscher AH; Wegerer S; Mizumoto S; Becker K; Dittler HJ; Fink U; Siewert JR
Clin Cancer Res; 2000 Aug; 6(8):3153-8. PubMed ID: 10955797
[TBL] [Abstract][Full Text] [Related]
3. p53 gene mutation and protein accumulation during neoplastic progression in Barrett's esophagus.
Bian YS; Osterheld MC; Bosman FT; Benhattar J; Fontolliet C
Mod Pathol; 2001 May; 14(5):397-403. PubMed ID: 11353048
[TBL] [Abstract][Full Text] [Related]
4. Molecular genetic analysis of surveillance biopsy samples from Barrett's mucosa--significance of sampling.
Werther M; Saure C; Pahl R; Schorr F; Rüschoff J; Alles JU; Heinmöller E
Pathol Res Pract; 2008; 204(5):285-94. PubMed ID: 18337019
[TBL] [Abstract][Full Text] [Related]
5. [Frequency and significance of APC gene mutations in malignant degeneration of Barrett esophagus].
Stöltzing O; Schneider PM; Becker K; Wegerer S; Siewert JR; Hölscher AH
Langenbecks Arch Chir Suppl Kongressbd; 1998; 115(Suppl I):485-9. PubMed ID: 14518303
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic significance of nuclear p53 expression in the surveillance of Barrett's esophagus--a longitudinal study.
Klump B; Hsieh CJ; Holzmann K; Borchard F; Gaco V; Greschniok A; Eckardt VF; Bettendorf U; Gregor M; Porschen R
Z Gastroenterol; 1999 Oct; 37(10):1005-11. PubMed ID: 10549095
[TBL] [Abstract][Full Text] [Related]
7. Aneuploidy and overexpression of Ki67 and p53 as markers for neoplastic progression in Barrett's esophagus: a case-control study.
Sikkema M; Kerkhof M; Steyerberg EW; Kusters JG; van Strien PM; Looman CW; van Dekken H; Siersema PD; Kuipers EJ
Am J Gastroenterol; 2009 Nov; 104(11):2673-80. PubMed ID: 19638963
[TBL] [Abstract][Full Text] [Related]
8. p53-mutant clones and field effects in Barrett's esophagus.
Prevo LJ; Sanchez CA; Galipeau PC; Reid BJ
Cancer Res; 1999 Oct; 59(19):4784-7. PubMed ID: 10519384
[TBL] [Abstract][Full Text] [Related]
9. p53 gene mutations in Barrett's epithelium and esophageal cancer.
Casson AG; Mukhopadhyay T; Cleary KR; Ro JY; Levin B; Roth JA
Cancer Res; 1991 Aug; 51(16):4495-9. PubMed ID: 1868473
[TBL] [Abstract][Full Text] [Related]
10. Beta 1 integrin expression in adenocarcinoma of Barrett's esophagus.
Bottger TC; Youssef V; Dutkowski P; Seifert J; Maschek H; Brenner W; Junginger T
Hepatogastroenterology; 1999; 46(26):938-43. PubMed ID: 10370643
[TBL] [Abstract][Full Text] [Related]
11. Clinical use of p53 in Barrett's esophagus.
Keswani RN; Noffsinger A; Waxman I; Bissonnette M
Cancer Epidemiol Biomarkers Prev; 2006 Jul; 15(7):1243-9. PubMed ID: 16835318
[TBL] [Abstract][Full Text] [Related]
12. Detection of genetic changes in Barrett's adenocarcinoma and Barrett's esophagus by DNA in situ hybridization and immunohistochemistry.
Krishnadath KK; Tilanus HW; Alers JC; Mulder AH; van Dekken H
Cytometry; 1994 Feb; 15(2):176-84. PubMed ID: 8168405
[TBL] [Abstract][Full Text] [Related]
13. p53 and ras gene expression in human esophageal cancer and Barrett's epithelium: a prospective study.
Sorsdahl K; Casson AG; Troster M; Van Meyel D; Inculet R; Chambers AF
Cancer Detect Prev; 1994; 18(3):179-85. PubMed ID: 8076380
[TBL] [Abstract][Full Text] [Related]
14. Progression of Barrett's metaplasia to adenocarcinoma is associated with the suppression of the transcriptional programs of epidermal differentiation.
Kimchi ET; Posner MC; Park JO; Darga TE; Kocherginsky M; Karrison T; Hart J; Smith KD; Mezhir JJ; Weichselbaum RR; Khodarev NN
Cancer Res; 2005 Apr; 65(8):3146-54. PubMed ID: 15833844
[TBL] [Abstract][Full Text] [Related]
15. The molecular biology of esophageal adenocarcinoma.
Koppert LB; Wijnhoven BP; van Dekken H; Tilanus HW; Dinjens WN
J Surg Oncol; 2005 Dec; 92(3):169-90. PubMed ID: 16299787
[TBL] [Abstract][Full Text] [Related]
16. Advances in gene chip technique in Barrett's metaplasia and adenocarcinoma.
Wang XW; Gao HJ; Fang DC
J Dig Dis; 2008 May; 9(2):68-71. PubMed ID: 18419638
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of TGF-beta1 in esophageal (Barrett's) adenocarcinoma is associated with advanced stage of disease and poor prognosis.
von Rahden BH; Stein HJ; Feith M; Pühringer F; Theisen J; Siewert JR; Sarbia M
Mol Carcinog; 2006 Oct; 45(10):786-94. PubMed ID: 16921482
[TBL] [Abstract][Full Text] [Related]
18. Dedifferentiation precedes invasion in the progression from Barrett's metaplasia to esophageal adenocarcinoma.
Helm J; Enkemann SA; Coppola D; Barthel JS; Kelley ST; Yeatman TJ
Clin Cancer Res; 2005 Apr; 11(7):2478-85. PubMed ID: 15814623
[TBL] [Abstract][Full Text] [Related]
19. Short-segment Barrett's esophagus associated with high-grade dysplasia.
Morita K; Fujimori T; Ono Y; Masuyama H; Nakamura T; Terano A
J Gastroenterol; 2002; 37(12):1083-5. PubMed ID: 12522544
[No Abstract] [Full Text] [Related]
20. p53 immunoreactivity in Barrett's metaplasia, dysplasia, and adenocarcinoma--a case report.
Kimura H; Konishi K; Kaji M; Maeda K; Yabushita K; Miwa A
Hepatogastroenterology; 2001; 48(42):1662-4. PubMed ID: 11813596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
